trial

Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse

NCTId NCT05480046
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Completed
Enrollment 275 (actual)
Sponsored by Rovi Pharmaceuticals Laboratories
Primary completion 2025-03-13
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
275 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2022-10-18
Primary completion
2025-03-13
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Risperidone

Sponsors

Rovi Pharmaceuticals LaboratoriesLead Sponsor

Investigators

1
Christoph U. Correll, MDStudy Chair

Sites

77 total
Aachen, GermanyAnsbach, GermanyBayreuth, GermanyBerlin, GermanyBerlin, GermanyBerlin, GermanyBonn, GermanyBonn, GermanyChemnitz, GermanyDortmund, GermanyEberswalde, GermanyEssen, Germany

Facts & assertions

4 sourced
Enrollment
275
Phase
NA
Primary Completion Date
2025-03-13
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
lead_sponsor
Rovi Pharmaceuticals Laboratories
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Christoph U. Correll, MD
person